mdlinx mdlinx
Neurology Articles on MDLinx

Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled Trial Journal of Pain and Symptom Management, 07/18/2011

Marineo G et al. – In this pilot randomized trial, Scrambler therapy appeared to relieve chronic neuropathic pain better than guideline–based drug management.

Methods
  • A clinical trial with patients randomized to either guideline–based pharmacological treatment or Scrambler therapy for a cycle of 10 daily sessions was performed.
  • Patients were matched by type of pain including postsurgical neuropathic pain, postherpetic neuralgia, or spinal canal stenosis.
  • Primary outcome was change in visual analog scale (VAS) pain scores at one month; secondary outcomes included VAS pain scores at two and three months, pain medication use, and allodynia.

Results
  • Fifty–two patients were randomized.
  • The mean VAS pain score before treatment was 8.1 points (control) and 8.0 points (Scrambler).
  • At one month, the mean VAS score was reduced from 8.1 to 5.8 (–28%) in the control group, and from 8 to 0.7 points (–91%) in the Scrambler group (P<0.0001).
  • At two and three months, the mean pain scores in the control group were 5.7 and 5.9 points, respectively, and 1.4 and 2 points in the Scrambler group, respectively (P<0.0001).
  • More relapses were seen in polyradicular pain than monoradicular pain, but retreatment and maintenance therapy gave relief.
  • No adverse effects were observed.

Read this article on Journal of Pain and Symptom Management



Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close